- Implant refinement and integration.
Long-term safety and efficacy testing in porcine models - Regulatory & Business plan
Treatments for neural damage
WE ARE COMMITED TO RELEASING THIS NOVEL MEDICAL TECHNOLOGY TO THE SOCIETY.
2023 – 2026
2026- 2027
- GMP-implant fabrication
- GLP porcine regulatory testing
2027- 2030
- Phase I / II clinical trials
- Human safety and efficacy testing
2030 – 2031
- CE marking
DREIMS is grounded in two decades of rigorous science searching for safe and effective therapeutics for neural damage.
We are developing a feasible plan to accomplish the remaining milestones.
